Details of the Drug Pharmacogenomic Perturbation Atlas

BMS-599626 Drug Info

BMS-599626; 714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID

10437018

ChEBI ID

CHEMBL1645462

CAS Number

CAS 714971-09-2

TTD Drug ID

D0U4FF

General Information of Drug (ID: DMDPQV5)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Asthma	-1.70	4.73e-2	25/31 (80.65%)	EPX;PRG2;FCER1G;...
Th1 and Th2 cell differentiation	-1.73	4.06e-2	80/92 (86.96%)	NFATC1;NFKBIB;NOTCH2;...
RNA degradation	-1.75	4.09e-2	53/79 (67.09%)	DCP1A;LSM2;LSM7;...
NF-kappa B signaling pathway	-1.75	4.12e-2	90/104 (86.54%)	LCK;CCL13;PARP1;...
Malaria	-1.77	3.56e-2	44/50 (88%)	SDC2;SELP;ACKR1;...
Transcriptional misregulation in cancer	-1.78	3.68e-2	158/192 (82.29%)	RELA;MYCN;KLF3;...
Mineral absorption	-1.79	4.14e-2	48/60 (80%)	MT1M;STEAP1;HMOX1;...
Chemokine signaling pathway	-1.81	4.38e-2	163/192 (84.9%)	CCL11;CXCR6;ADCY1;...
Protein digestion and absorption	-1.85	2.66e-2	78/103 (75.73%)	SLC36A1;FXYD2;ATP1A2;...
Rheumatoid arthritis	-1.88	2.45e-2	78/93 (83.87%)	FLT1;TEK;CD86;...
Bladder cancer	-1.98	3.07e-3	40/41 (97.56%)	MAP2K1;HRAS;CDKN1A;...
TNF signaling pathway	-2.00	4.09e-3	103/112 (91.96%)	CASP10;CREB3L1;IL18R1;...
Cytokine-cytokine receptor interaction	-2.03	6.13e-3	246/295 (83.39%)	TNFSF8;IFNB1;EPOR;...
Viral protein interaction with cytokine and cytokine re...	-2.34	0.00e+0	84/100 (84%)	IL20RA;CCL8;LTBR;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 10uM	24H